重庆科润生物完成数千万A轮融资 致力于开发眼科等创新生物药
3月20日消息，重庆科润于近日完成数千万元A轮融资。本轮融资由重庆智睿投资有限公司独家投资，所募集资金将主要用于推进多款眼科及肿瘤管线产品临床前及临床研究、平台建设，进一步加快研发进度，为产品的商业化奠定坚实基础。
据悉，重庆科润生物是国内一家专注于治疗用重组蛋白药物开发的具有领先技术的企业。在20多年的发展过程中，公司深耕医药生物领域，专注于酵母、原核表达系统，已建立起大规模包涵体复性、以白蛋白纳米抗体为基础的长效化蛋白、纳米抗体等多个核心技术平台。2010年，所建立的酵母表达中试技术平台获得国家科技部“十一五”重大科技专项资助，标志着平台技术实力受到行业认可。基于对行业的前瞻性认知，科润生物始终坚持差异化的策略，重点聚焦眼科等领域，开发出多款生物新药，形成了丰富的、具有竞争力的产品管线。公司成熟领先的创新技术平台，为可持续开发出具有竞争优势及商业化前景的生物药夯实了发展基础。
在产品管线上，1项生物1类新药为国内独家品种，正处于II/III期临床研究阶段；首个用于神经营养性角膜炎的重组人神经生长因子滴眼液，已于2022年11月21日获得临床默许。该产品作为国内首个该适应症的品种，填补了在该领域的治疗空白，具有广阔的市场空间。保守估算，市场容量超过500亿，销售峰值可达30亿。科润生物与国际顶尖创新药科学家合作，正在开发3款全球首创新药，取得突破性进展，今年底申请国际专利，加速科润创新转型的发展步伐。此外，在眼科管线方面，还布局近10款针对难治愈的中重度干眼症、非感染性葡萄膜炎、甲状腺眼病等疾病的生物大分子眼科药物。
本轮独家投资方——重庆智睿投资有限公司是上市公司智飞生物（股票代码：300122）与其控股股东蒋仁生先生共同出资设立的股权投资公司，注册资本20亿元。智睿投资致力于生物药物的开发和产业化，积极跟踪全球前沿技术，借助优秀的科研人才、厚实的资本支撑，推动生物医药行业的发展。
科润生物创始人、CEO李树刚博士表示，感谢新老投资人的信任和支持。在新一轮融资的助推下，科润生物将牢牢把握机遇，坚持差异化的产品开发策略，继续专注于眼科等未满足临床需求的重大疾病领域，依托积累的技术优势，大力开发临床急需、替代进口、患者可及的高质量生物创新药。在新老投资人的支持下，公司加快商业化的步伐，在创新药领域实现突破性发展，力争成为眼科大分子药物领域全产业链的国内领先企业，为人类的健康事业贡献微薄的力量。
公司欢迎与业界同行深入交流，探讨合作机会，共创生物药的美好未来！
{"weixin":{"label":"微信","name":"weixin","selected":true,"value":false,"sortid":"1","shareid":"weixin","sharetitle":"分享到微信","event":"shareToWeiXin","lang":"shareWeb_WeiXin"},"copy":{"label":"复制网址","name":"copy","selected":true,"value":false,"sortid":"2","shareid":"copy","sharetitle":"复制网址","event":"copy_url","lang":"shareWeb_Copy"},"qq":{"label":"QQ好友","name":"qq","selected":true,"value":false,"sortid":"2","shareid":"qq","sharetitle":"分享到QQ","event":"shareToQQ","lang":"shareWeb_QQ"},"sina_weibo":{"label":"新浪微博","name":"sina_weibo","selected":true,"value":false,"sortid":"4","shareid":"sina_weibo","sharetitle":"分享到新浪微博","event":"shareToSinaWB","lang":"shareWeb_SinaWeiBo"},"qq_zone":{"label":"QQ空间","name":"qq_zone","selected":true,"value":false,"sortid":"5","shareid":"qq_zone","sharetitle":"分享到QQ空间","event":"shareToQzone","lang":"shareWeb_QQZone"},"renren":{"label":"人人网","name":"renren","selected":true,"value":false,"sortid":"7","shareid":"renren","sharetitle":"分享到人人网","event":"shareToRenren","lang":"shareWeb_RenRen"},"douban":{"label":"豆瓣网","name":"douban","selected":true,"value":false,"sortid":"8","shareid":"douban","sharetitle":"分享到豆瓣网","event":"shareToDouban","lang":"shareWeb_DouBan"},"baidu_tieba":{"label":"百度贴吧","name":"baidu_tieba","selected":true,"value":false,"sortid":"10","shareid":"baidu_tieba","sharetitle":"分享到百度贴吧","event":"shareToTieba","lang":"shareWeb_TieBa"},"Facebook":{"label":"Facebook","name":"Facebook","selected":true,"value":true,"sortid":"11","shareid":"Facebook","sharetitle":"分享到FaceBook","event":"shareToFacebook","lang":"shareWeb_Facebook"},"Twitter":{"label":"Twitter","name":"Twitter","selected":true,"value":true,"sortid":"12","shareid":"Twitter","sharetitle":"分享到Twitter","event":"shareToTwitter","lang":"shareWeb_Twitter"},"LinkedIn":{"label":"LinkedIn","name":"LinkedIn","selected":true,"value":true,"sortid":"13","shareid":"LinkedIn","sharetitle":"分享到linkedIn","event":"shareToLinkedin","lang":"shareWeb_Linkedin"},"whatsapp":{"label":"whatsapp","name":"whatsapp","selected":true,"value":true,"sortid":"15","shareid":"whatsapp","sharetitle":"分享到whatsapp","event":"shareToWhatsapp","lang":"shareWeb_whatsapp"},"line":{"label":"line","name":"line","selected":true,"value":true,"sortid":"15","shareid":"line","sharetitle":"分享到line","event":"shareToLine","lang":"shareWeb_line"},"qq_weibo":{"label":"腾讯微博","name":"qq_weibo","selected":true,"value":true,"sortid":"3","shareid":"qq_weibo","sharetitle":"分享到腾讯微博","event":"shareToQQwb","lang":"shareWeb_QQWeiBo"},"peopleBlog":{"label":"人民微博","name":"propleBlog","selected":true,"value":true,"sortid":"14","shareid":"propleBlog","sharetitle":"分享到人民微博","event":"shareToPeopleBlog","lang":"shareWeb_peopleBlog"}}